Fidelity Investments’s Monopar Therapeutics MNPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$46K Buy
578
+48
+9% +$5.15K ﹤0.01% 4375
2026
Q2
$49.1K Buy
530
+121
+30% +$7.49K ﹤0.01% 4314
2026
Q1
$22.4K Buy
409
+51
+14% +$3.08K ﹤0.01% 4467
2025
Q4
$23.4K Buy
358
+8
+2% +$654 ﹤0.01% 4408
2025
Q3
$28.6K Buy
350
+319
+1,029% +$14.3K ﹤0.01% 4211
2025
Q2
$1.11K Buy
+31
New +$1.13K ﹤0.01% 4951
2024
Q2
– Sell
-1,100
Closed -$3.75K – 5537
2024
Q1
$3.75K Buy
+1,100
New +$3.28K ﹤0.01% 4584
2023
Q3
– Sell
-30
Closed -$128 – 5436
2023
Q2
$128 Buy
+30
New +$153 ﹤0.01% 4943
2022
Q3
– Sell
-2
Closed -$22 – 5474
2022
Q2
$22 Buy
+2
New +$23 ﹤0.01% 5201

Other funds holding MNPR

Fidelity Investments's MNPR Position: Q3 2026 in Review

Fidelity Investments increased its Monopar Therapeutics (MNPR) stake by 9.1% in Q3 2026, buying an estimated $5.15K and bringing the position to 578 shares worth $46K. The position accounts for ﹤0.01% of the portfolio, ranked #4375.

Fidelity Investments first reported a position in MNPR in Q2 2022 and has held it in 9 quarters since. The position peaked at $49.1K in Q2 2026. 106 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.

  • Fidelity Investments held 578 shares of Monopar Therapeutics worth $46K as of Q3 2026.
  • Fidelity Investments bought 48 Monopar Therapeutics shares in Q3 2026, an estimated $5.15K.
  • Monopar Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #4375 holding.
  • Fidelity Investments first reported a position in Monopar Therapeutics in Q2 2022 and has held it in 9 quarters since.
  • Fidelity Investments's Monopar Therapeutics position peaked at $49.1K in Q2 2026.
  • 106 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.